Clinical Significance of Tissue Factor–Exposing Microparticles in Arterial and Venous Thrombosis

Nick van Es; Suzanne Bleker; Auguste Sturk; Rienk Nieuwland

doi:10.1055/s-0035-1556047

Seminars in Thrombosis and Hemostasis, Inhaltsverzeichnis

Semin Thromb Hemost 2015; 41(07): 718-727
DOI: 10.1055/s-0035-1556047

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Clinical Significance of Tissue Factor–Exposing Microparticles in Arterial and Venous Thrombosis

Autor*innen

Nick van Es

¹Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
Suzanne Bleker

¹Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
Auguste Sturk

²Department of Clinical Chemistry, Academic Medical Center, Amsterdam, The Netherlands
Rienk Nieuwland

²Department of Clinical Chemistry, Academic Medical Center, Amsterdam, The Netherlands

Abstract

Microparticles (MP) are small extracellular vesicles (30–1,000 nm) that are released from activated cells or platelets. Exposure of negatively charged phospholipids and tissue factor (TF) renders MP procoagulant. Normal plasma levels of intravascular TF-exposing MP (TFMP) are low, but their number may rise in pathological conditions, including cancer and infectious disease. Emerging evidence indicates an important role for these circulating TFMP in the pathogenesis of thrombotic complications such as venous thromboembolism and disseminated intravascular coagulation, whereas their contribution to arterial thrombosis is less studied. Despite serious limitations of the currently available assays for measuring TFMP levels or the procoagulant activity associated with TFMP with respect to sensitivity and specificity, the scientific interest in TFMP is rapidly growing because their application as prognostic biomarkers for thrombotic complications is promising. Future advances in detection methods will likely provide more insight into TFMP and eventually improve their clinical utility.

Keywords

tissue factor - microparticles - venous thromboembolism - arterial thrombosis - extracellular vesicles

Volltext

Referenzen

References
1 Lozano R, Naghavi M, Foreman K , et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380 (9859) 2095-2128
2 Raskob GE, Angchaisuksiri P, Blanco AN , et al; ISTH Steering Committee for World Thrombosis Day. Thrombosis: a major contributor to global disease burden. Arterioscler Thromb Vasc Biol 2014; 34 (11) 2363-2371
3 Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med 2013; 368 (21) 2004-2013
4 Virchow R. Ueber die Erweiterung kleinerer Gefäfse. Arch Pathol Anat Physiol Klin Med 1851; 3 (3) 427-462
5 Mackman N. New insights into the mechanisms of venous thrombosis. J Clin Invest 2012; 122 (7) 2331-2336
6 van der Pol E, Böing AN, Harrison P, Sturk A, Nieuwland R. Classification, functions, and clinical relevance of extracellular vesicles. Pharmacol Rev 2012; 64 (3) 676-705
7 Wolf P. The nature and significance of platelet products in human plasma. Br J Haematol 1967; 13 (3) 269-288
8 Yuana Y, Sturk A, Nieuwland R. Extracellular vesicles in physiological and pathological conditions. Blood Rev 2013; 27 (1) 31-39
9 van der Pol E, Coumans F, Varga Z, Krumrey M, Nieuwland R. Innovation in detection of microparticles and exosomes. J Thromb Haemost 2013; 11 (Suppl. 01) 36-45
10 Diamant M, Nieuwland R, Pablo RF, Sturk A, Smit JWA, Radder JK. Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus. Circulation 2002; 106 (19) 2442-2447
11 Versteeg HH, Heemskerk JWM, Levi M, Reitsma PH. New fundamentals in hemostasis. Physiol Rev 2013; 93 (1) 327-358
12 Thomas GM, Panicot-Dubois L, Lacroix R, Dignat-George F, Lombardo D, Dubois C. Cancer cell-derived microparticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo. J Exp Med 2009; 206 (9) 1913-1927
13 Falati S, Liu Q, Gross P , et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med 2003; 197 (11) 1585-1598
14 van der Pol E, Coumans FA, Grootemaat AE , et al. Particle size distribution of exosomes and microvesicles determined by transmission electron microscopy, flow cytometry, nanoparticle tracking analysis, and resistive pulse sensing. J Thromb Haemost 2014; 12 (7) 1182-1192
15 Arraud N, Linares R, Tan S , et al. Extracellular vesicles from blood plasma: determination of their morphology, size, phenotype and concentration. J Thromb Haemost 2014; 12 (5) 614-627
16 Khorana AA, Francis CW, Menzies KE , et al. Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost 2008; 6 (11) 1983-1985
17 Tesselaar MET, Romijn FPHTM, Van Der Linden IK, Prins FA, Bertina RM, Osanto S. Microparticle-associated tissue factor activity: a link between cancer and thrombosis?. J Thromb Haemost 2007; 5 (3) 520-527
18 Berckmans RJ, Sturk A, van Tienen LM, Schaap MCL, Nieuwland R. Cell-derived vesicles exposing coagulant tissue factor in saliva. Blood 2011; 117 (11) 3172-3180
19 van Doormaal F, Kleinjan A, Berckmans RJ , et al. Coagulation activation and microparticle-associated coagulant activity in cancer patients. An exploratory prospective study. Thromb Haemost 2012; 108 (1) 160-165
20 Tatsumi K, Antoniak S, Monroe III DM, Khorana AA, Mackman N ; Subcommittee on Hemostasis and Malignancy. Evaluation of a new commercial assay to measure microparticle tissue factor activity in plasma: communication from the SSC of the ISTH. J Thromb Haemost 2014; 12 (11) 1932-1934
21 Lacroix R, Judicone C, Mooberry M, Boucekine M, Key NS, Dignat-George F ; The ISTH SSC Workshop. Standardization of pre-analytical variables in plasma microparticle determination: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop. J Thromb Haemost 2013;
22 Hron G, Kollars M, Weber H , et al. Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb Haemost 2007; 97 (1) 119-123
23 Campello E, Zabeo E, Radu CM , et al. Hypercoagulability in overweight and obese subjects who are asymptomatic for thrombotic events. Thromb Haemost 2015; 113 (1) 85-96
24 Lee RD, Barcel DA, Williams JC , et al. Pre-analytical and analytical variables affecting the measurement of plasma-derived microparticle tissue factor activity. Thromb Res 2012; 129 (1) 80-85
25 Franz C, Böing AN, Hau CM , et al. Procoagulant tissue factor-exposing vesicles in human seminal fluid. J Reprod Immunol 2013; 98 (1–2) 45-51
26 Berckmans RJ, Nieuwland R, Tak PP , et al. Cell-derived microparticles in synovial fluid from inflamed arthritic joints support coagulation exclusively via a factor VII-dependent mechanism. Arthritis Rheum 2002; 46 (11) 2857-2866
27 Berckmans RJ, Nieuwland R, Böing AN, Romijn FP, Hack CE, Sturk A. Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb Haemost 2001; 85 (4) 639-646
28 Geddings JE, Mackman N. Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients. Blood 2013; 122 (11) 1873-1880
29 Nieuwland R, Berckmans RJ, McGregor S , et al. Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood 2000; 95 (3) 930-935
30 Baker JV, Huppler Hullsiek K, Bradford RL, Prosser R, Tracy RP, Key NS. Circulating levels of tissue factor microparticle procoagulant activity are reduced with antiretroviral therapy and are associated with persistent inflammation and coagulation activation among HIV-positive patients. J Acquir Immune Defic Syndr 2013; 63 (3) 367-371
31 Matijevic N, Wang Y-WW, Wade CE , et al; PROMMTT Study Group. Cellular microparticle and thrombogram phenotypes in the Prospective Observational Multicenter Major Trauma Transfusion (PROMMTT) study: correlation with coagulopathy. Thromb Res 2014; 134 (3) 652-658
32 Bastarache JA, Fremont RD, Kropski JA, Bossert FR, Ware LB. Procoagulant alveolar microparticles in the lungs of patients with acute respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol 2009; 297 (6) L1035-L1041
33 Patil R, Ghosh K, Satoskar P, Shetty S. Elevated procoagulant endothelial and tissue factor expressing microparticles in women with recurrent pregnancy loss. PLoS ONE 2013; 8 (11) e81407
34 Biró E, Sturk-Maquelin KN, Vogel GMT , et al. Human cell-derived microparticles promote thrombus formation in vivo in a tissue factor-dependent manner. J Thromb Haemost 2003; 1 (12) 2561-2568
35 Thaler J, Koppensteiner R, Pabinger I, Ay C, Gremmel T. Microparticle-associated tissue factor activity in patients with acute unprovoked deep vein thrombosis and during the course of one year. Thromb Res 2014; 134 (5) 1093-1096
36 Garcia Rodriguez P, Eikenboom HCJ, Tesselaar MET , et al. Plasma levels of microparticle-associated tissue factor activity in patients with clinically suspected pulmonary embolism. Thromb Res 2010; 126 (4) 345-349
37 Campello E, Spiezia L, Radu CM , et al. Endothelial, platelet, and tissue factor-bearing microparticles in cancer patients with and without venous thromboembolism. Thromb Res 2011; 127 (5) 473-477
38 Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood 2013; 122 (10) 1712-1723
39 van den Berg YW, Osanto S, Reitsma PH, Versteeg HH. The relationship between tissue factor and cancer progression: insights from bench and bedside. Blood 2012; 119 (4) 924-932
40 Auwerda JJA, Yuana Y, Osanto S , et al. Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma. Thromb Haemost 2011; 105 (1) 14-20
41 Thaler J, Koder S, Kornek G, Pabinger I, Ay C. Microparticle-associated tissue factor activity in patients with metastatic pancreatic cancer and its effect on fibrin clot formation. Transl Res 2014; 163 (2) 145-150
42 Thaler J, Ay C, Mackman N , et al. Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients. J Thromb Haemost 2012; 10 (7) 1363-1370
43 Bharthuar A, Khorana AA, Hutson A , et al. Circulating microparticle tissue factor, thromboembolism and survival in pancreaticobiliary cancers. Thromb Res 2013; 132 (2) 180-184
44 Tesselaar MET, Romijn FPHTM, van der Linden IK, Bertina RM, Osanto S. Microparticle-associated tissue factor activity in cancer patients with and without thrombosis. J Thromb Haemost 2009; 7 (8) 1421-1423
45 Zwicker JI, Liebman HA, Neuberg D , et al. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res 2009; 15 (22) 6830-6840
46 Zwicker JI, Liebman HA, Bauer KA , et al. Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study). Br J Haematol 2013; 160 (4) 530-537
47 Haubold K, Rink M, Spath B , et al. Tissue factor procoagulant activity of plasma microparticles is increased in patients with early-stage prostate cancer. Thromb Haemost 2009; 101 (6) 1147-1155
48 Manly DA, Wang J, Glover SL , et al. Increased microparticle tissue factor activity in cancer patients with Venous Thromboembolism. Thromb Res 2010; 125 (6) 511-512
49 Sartori MT, Della Puppa A, Ballin A , et al. Circulating microparticles of glial origin and tissue factor bearing in high-grade glioma: a potential prothrombotic role. Thromb Haemost 2013; 110 (2) 378-385
50 Hernández C, Orbe J, Roncal C , et al. Tissue factor expressed by microparticles is associated with mortality but not with thrombosis in cancer patients. Thromb Haemost 2013; 110 (3) 598-608
51 Hunt BJ. Bleeding and coagulopathies in critical care. N Engl J Med 2014; 370 (9) 847-859
52 Osterud B, Flaegstad T. Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: related to an unfavourable prognosis. Thromb Haemost 1983; 49 (1) 5-7
53 Øvstebø R, Aass HCD, Haug KBF , et al. LPS from Neisseria meningitidis is crucial for inducing monocyte- and microparticle-associated tissue factor activity but not for tissue factor expression. Innate Immun 2012; 18 (4) 580-591
54 Aras O, Shet A, Bach RR , et al. Induction of microparticle- and cell-associated intravascular tissue factor in human endotoxemia. Blood 2004; 103 (12) 4545-4553
55 Hellum M, Øvstebø R, Brusletto BS, Berg JP, Brandtzaeg P, Henriksson CE. Microparticle-associated tissue factor activity correlates with plasma levels of bacterial lipopolysaccharides in meningococcal septic shock. Thromb Res 2014; 133 (3) 507-514
56 Woei-A-Jin FJSH, van der Starre WE, Tesselaar MET , et al. Procoagulant tissue factor activity on microparticles is associated with disease severity and bacteremia in febrile urinary tract infections. Thromb Res 2014; 133 (5) 799-803
57 Świtońska M, Słomka A, Sinkiewicz W, Żekanowska E. Tissue-factor-bearing microparticles (MPs-TF) in patients with acute ischaemic stroke: the influence of stroke treatment on MPs-TF generation. Eur J Neurol 2015; 22 (2) 395-e29
58 Stępień E, Stankiewicz E, Zalewski J, Godlewski J, Zmudka K, Wybrańska I. Number of microparticles generated during acute myocardial infarction and stable angina correlates with platelet activation. Arch Med Res 2012; 43 (1) 31-35
59 Huisse M-G, Lanoy E, Tcheche D , et al. Prothrombotic markers and early spontaneous recanalization in ST-segment elevation myocardial infarction. Thromb Haemost 2007; 98 (2) 420-426
60 Keuren JFW, Jie K-SG, Leers MPG. Increased expression of TF on monocytes, but decreased numbers of TF bearing microparticles in blood from patients with acute myocardial infarction. Eur J Haematol 2009; 83 (4) 387-388
61 Maly M, Hrachovinova I, Tomasov P, Salaj P, Hajek P, Veselka J. Patients with acute coronary syndromes have low tissue factor activity and microparticle count, but normal concentration of tissue factor antigen in platelet free plasma: a pilot study. Eur J Haematol 2009; 82 (2) 148-153
62 Morel O, Pereira B, Averous G , et al. Increased levels of procoagulant tissue factor-bearing microparticles within the occluded coronary artery of patients with ST-segment elevation myocardial infarction: role of endothelial damage and leukocyte activation. Atherosclerosis 2009; 204 (2) 636-641
63 Leroyer AS, Isobe H, Lesèche G , et al. Cellular origins and thrombogenic activity of microparticles isolated from human atherosclerotic plaques. J Am Coll Cardiol 2007; 49 (7) 772-777
64 Schmidt M, Cannegieter SC, Johannesdottir SA, Dekkers OM, Horváth-Puhó E, Sørensen HT. Statin use and venous thromboembolism recurrence: a combined nationwide cohort and nested case-control study. J Thromb Haemost 2014; 12 (8) 1207-1215
65 Glynn RJ, Danielson E, Fonseca FA , et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009; 360 (18) 1851-1861
66 Owens III AP, Byrnes JR, Mackman N. Hyperlipidemia, tissue factor, coagulation, and simvastatin. Trends Cardiovasc Med 2014; 24 (3) 95-98
67 Matsumoto N, Nomura S, Kamihata H, Kimura Y, Iwasaka T. Increased level of oxidized LDL-dependent monocyte-derived microparticles in acute coronary syndrome. Thromb Haemost 2004; 91 (1) 146-154
68 Owens III AP, Passam FH, Antoniak S , et al. Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin. J Clin Invest 2012; 122 (2) 558-568
69 Davila M, Robles-Carrillo L, Unruh D , et al. Microparticle association and heterogeneity of tumor-derived tissue factor in plasma: is it important for coagulation activation?. J Thromb Haemost 2014; 12 (2) 186-196